CSPC Innovation Pharmaceutical

CSPC Innovation Pharmaceutical

300765.SZPre-clinical

CSPC Innovation Pharmaceutical is a publicly-traded Chinese biotech company that serves as the innovation arm of CSPC Pharmaceutical Group, one of China's largest pharmaceutical companies. The company focuses on developing first-in-class and best-in-class therapeutics through internal R&D and strategic partnerships. With a robust pipeline spanning oncology, immunology, and metabolic diseases, CSPC Innovation aims to address unmet medical needs in both domestic Chinese and international markets.

Market Cap
$6.2B
Employees
1,000-5,000
Focus
Biotech

300765.SZ · Stock Price

USD 30.16+23.19 (+332.57%)

Historical price data

AI Company Overview

CSPC Innovation Pharmaceutical is a publicly-traded Chinese biotech company that serves as the innovation arm of CSPC Pharmaceutical Group, one of China's largest pharmaceutical companies. The company focuses on developing first-in-class and best-in-class therapeutics through internal R&D and strategic partnerships. With a robust pipeline spanning oncology, immunology, and metabolic diseases, CSPC Innovation aims to address unmet medical needs in both domestic Chinese and international markets.

Technology Platform

Integrated drug discovery and development platform focusing on small molecules and biologics for diseases with high unmet medical need, particularly in therapeutic areas relevant to Chinese patient populations.

Opportunities

CSPC Innovation is well-positioned to capitalize on China's growing pharmaceutical market, government support for domestic innovation, and the expanding middle class's demand for advanced healthcare solutions.

Risk Factors

Key risks include intense competition from global pharmaceutical companies, regulatory uncertainties, clinical development risks, and potential geopolitical tensions affecting international market access and partnerships.

Competitive Landscape

The company competes with established international pharmaceutical giants like Roche and Pfizer, as well as emerging Chinese biotech companies such as BeiGene and Innovent Biologics. Its competitive advantage lies in strong financial backing and deep understanding of the Chinese market.

Patents
1

Company Info

TypeTherapeutics
Employees1,000-5,000
LocationChina
StagePre-clinical
RevenueRevenue Generating

Trading

Ticker300765.SZ
ExchangeShenzhen Stock Exchange

Contact

Therapeutic Areas

OncologyAutoimmune DiseasesMetabolic DisordersCentral Nervous System
SIMILAR COMPANIES
Innovent Biologics
Innovent Biologics
Pre-clinical · Suzhou
Hansoh Pharma
Hansoh Pharma
Pre-clinical ·
CSPC Pharmaceutical Group Limited
CSPC Pharmaceutical Group Limited
Pre-clinical ·
Sinopharm
Sinopharm
Pre-clinical ·
Tong Ren Tang
Tong Ren Tang
Pre-clinical ·
Is this your company?

Claim your profile to update information, add pipeline data, and connect with investors.

Claim profile